Results 131 to 140 of about 23,004 (191)

Can atypical antipsychotics alleviate Deficits in psychosocial impairments in patients with a diagnosis of Borderline Personality? A systematic review and meta-analysis.

Psychiatry Res Commun
Griffiths K, Velichkova N, Quadt L, Berni J.   +3 more
europepmc   +1 more source

Efficacy and tolerability of FDA-approved atypical antipsychotics for the treatment of bipolar depression: a systematic review and network meta-analysis. [PDF]

Eur Psychiatry
Li S, Xu C, Hu S, Lai J.
europepmc   +1 more source

Healthcare resource utilization among nursing home residents with Parkinson's disease psychosis: an analysis of Medicare beneficiaries treated with pimavanserin or other-atypical antipsychotics. [PDF]

J Comp Eff Res
Rajagopalan K, Rashid N, Gopal D, Doshi D.   +3 more
europepmc   +1 more source

An economic model to understand the cost-effectiveness of olanzapine orally dispersible tablets (ODT) and olanzapine film coated tablets as a group compared with other oral atypical antipsychotics for treating schizophrenia in Morocco. [PDF]

Ann Gen Psychiatry
Tazi A, Errachidi F, Sonawane D, Tahri G, Rao S, Mehta S.   +5 more
europepmc   +1 more source